Table 3.
Treatments and outcomes of patients with COVID-19.
| Duration of viral sheddinga |
||||
|---|---|---|---|---|
| Treatments and outcomes | All patients (n = 147) | >17 days (n = 65) | ≤17 days (n = 82) | p value |
| Treatments | ||||
| Antiviral treatment | 147 (100%) | 65 (100%) | 82 (100%) | NA |
| Antibioticsb | 64 (47%) | 34 (56%) | 30 (40%) | 0.058 |
| Glucocorticoids | 39 (28%) | 24 (37%) | 15 (20%) | 0.020 |
| Immunoglobulin | 37 (26%) | 23 (35%) | 14 (18%) | 0.022 |
| Nasal cannula | 138 (94%) | 60 (92%) | 78 (95%) | 0.509 |
| High flow nasal cannula | 5 (3%) | 3 (5%) | 2 (3%) | 0.655 |
| Non-invasive ventilation | 1 (1%) | 1 (2%) | 0 | 0.441 |
| Invasive ventilation | 0 | 0 | 0 | |
| ECMO | 0 | 0 | 0 | |
| Outcomes | ||||
| ARDS | 7 (5%) | 4 (6%) | 3 (4%) | 0.700 |
| AKI | 1 (1%) | 0 | 1 (1%) | 1.000 |
| MODS | 1 (1%) | 0 | 1 (1%) | 1.000 |
| Hospital length of stay, days | ||||
| Median (IQR) | 13.0 (11.0−17.5) | 16.0 (12.0−24.0) | 12.0 (10.0−15.0) | <0.001 |
| Range | 5.0−37.0 | 5.0−37.0 | 5.0−24.0 | |
Abbreviation: COVID-19, coronavirus disease 2019; NA, not applicable; ECMO, extracorporeal membrane oxygenation; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; MODS, multiple organ dysfunction syndrome.
a
The number of days from the symptoms onset till the successive negative detection of SARS-CoV-2 RNA.
b
Data regarding antibiotics were missing for 10 patients (7%).